# NGeneBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ngenebio

- Industry: Healthcare
- Headquarters: Seoul, South Korea
- Website: www.ngenebio.com
- Total disclosed funding: $10M
- Latest round: Series B (Nov 20, 2018)
- Investors on record: 8

## About

Founded in 2015 and based in Seoul, South Korea, NGeneBio develops in vitro diagnostics (IVD) and companion diagnostics (CDx) products for hereditary breast and ovarian cancer. In December 2020, NGeneBio raised KRW 34.216 billion in an IPO, selling 2.444 million shares at KRW 14,000 per share on the KOSDAQ

## Funding rounds

- Series B, Nov 20, 2018, $10M — SL Investment, DSC Investment, IMM Investment, UTC Investment, NAU IB Capital, P&I Investment, K-Run Ventures
- Series A, Jun 1, 2017 — Korea Investment Partners

## Investors

- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A
- SL Investment (https://capitalatlas.ai/funds/sl-investment) — Series B
- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series B
- IMM Investment (https://capitalatlas.ai/funds/imm-investment) — Series B
- UTC Investment (https://capitalatlas.ai/funds/utc-investment) — Series B
- NAU IB Capital (https://capitalatlas.ai/funds/nau-ib-capital) — Series B
- P&I Investment (https://capitalatlas.ai/funds/p-i-investment) — Series B
- K-Run Ventures (https://capitalatlas.ai/funds/k-run-ventures) — Series B